Managing the Drug Discovery Process, Second Editionthoroughly examines the current state of pharmaceutical research and development by providing chemistry-based perspectives on biomedical research, drug hunting and innovation. The book also considers the interplay of stakeholders, consumers and the drug firm with attendant factors, including those that are technical, legal, economic, demographic, political, social, ecological and infrastructural. This new edition takes a closer look at increasing pre-approval costs for new drugs and examines not only why these increases occur, but also how they can be overcome to ensure a robust pharmacoeconomic future. Since drug research can be a high-risk, high-payoff industry, it is important to researchers to effectively and strategically manage the drug discovery process. All chapters in this new release have been revised and expanded with new discussions on genetic and epigenetic advances, including CRISPR, exosomes, immuno-oncology approaches, including checkpoint inhibitors and CAR-T, antibiotics, entrepreneurship, and AI. Considers drug discovery in multiple R&D venues, including big pharma, large biotech, start-up ventures, academia and nonprofit research institutesAnalyzes the organization of pharmaceutical R&D, taking into account human resources considerations like recruitment and configuration, management of discovery and development processes, and the coordination of internal research within, and beyond, the organization, including outsourced workPresents a consistent, well-connected, and logical dialogue that readers will find both comprehensive and approachableAddresses new areas, including gene editing technologies like CRISPR, personalized medicine, ethical and moral issues, data visualization, statistical representations, AI and machine learning | Managing the Drug Discovery Process by Susan Miller, Paperback | Indigo Chapters